U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market 21.2 CAGR Growth Outlook 2024-2030

Key Insights

The U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market size was valued at USD 4.34 USD Billion in 2023 and is projected to reach USD 16.67 USD Billion by 2032, exhibiting a CAGR of 21.2 % during the forecast period. Secondary hyperparathyroidism (SHPT) in the United States is a disease where the parathyroid glands in the body are overactive and produce more of the parathyroid hormone than necessary because of situations such as chronic renal diseases. Treatment is directed at maintaining the levels of calcium and phosphorus to the normal values to prevent complications such as renal osteodystrophy and calcification of blood vessels. These include calcimimetics for the treatment of secondary hyperparathyroidism, vitamin D for hypoparathyroidism, and phosphate binders for patients with hyperphosphatemic states. Cinacalcet is an example of a calcimimetic agent that lowers the PTH levels by activating the calcium-sensing receptors. Calcium- and phosphorus-binding medications such as paricalcitol or doxercalciferol can be useful as well. Phosphorus lowering or phosphate binders include sevelamer or lanthanum carbonate for combating serum phosphorus levels. These treatment prevents the elongation of SHPT and aim to enhance mineral and hormonal concentrations, bone density and other cardiovascular risks.

U.S. Secondary Hyperparathyroidism (SHPT) Treatment Trends

The U.S. SHPT Treatment Market is witnessing several significant trends, including:

• Increasing adoption of calcimimetics as first-line therapy
• Growing use of combination therapies involving calcimimetics and phosphate binders
• Emergence of novel SHPT treatments, such as parathyroid hormone (PTH) inhibitors

Driving Forces: What's Propelling the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market

• Exponential rise in end-stage renal disease (ESRD) and chronic kidney disease (CKD) cases
• Enhanced comprehension of the fundamental mechanisms underlying SHPT development and progression
• Rapid advancements in treatment modalities, including novel pharmacotherapies and surgical interventions
• Growing healthcare professional awareness and understanding of SHPT's impact on patient outcomes
• Ample governmental support for research initiatives focused on improving SHPT management strategies

Challenges and Restraints in the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market

• High cost of SHPT treatments
• Limited reimbursement coverage for some SHPT medications
• Potential side effects associated with SHPT treatments
• Lack of awareness of SHPT among patients and general population

Emerging Trends in U.S. Secondary Hyperparathyroidism (SHPT) Treatment

• Development of new and improved calcimimetics
• Exploration of novel targets for SHPT treatment, such as fibroblast growth factor 23 (FGF23)
• Increasing use of telemedicine for SHPT management
• Personalized medicine approaches to tailor treatment based on individual patient characteristics

Growth Catalysts in U.S. Secondary Hyperparathyroidism (SHPT) Treatment Industry

• Rising demand for effective and well-tolerated SHPT treatments
• Growing focus on improving patient outcomes in CKD and ESRD
• Government support for innovative SHPT therapies
• Partnerships and collaborations among pharmaceutical companies and research institutions

Market Segmentation: U.S. Secondary Hyperparathyroidism (SHPT) Treatment Analysis

• Drug Class: Calcimimetics (e.g., Cinacalcet, Evocalcet), Vitamin D Analogues (e.g., Calcitriol, Paricalcitol), Phosphate Binders (e.g., Sevelamer, Lanthanum Carbonate)
• Distribution Channel: Hospital & Retail Pharmacies, Online Channels, Others

Leading Players in the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market

• Amgen Inc.
• Teva Pharmaceutical Industries Ltd.
• Genzyme Corporation (Sanofi)
• AbbVie Inc.
• Cipla Inc.
• Dr. Reddy's Laboratories Ltd.
• OPKO Health, Inc.

Significant Developments in the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Sector

• Launch of new SHPT medications, such as etelcalcetide and burosumab
• Expansion of clinical trials to evaluate novel SHPT treatments
• Growing adoption of patient-centric approaches to SHPT management

Comprehensive Coverage U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market Report

Our meticulously crafted report offers an in-depth analysis of the burgeoning U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market, encompassing:

• Comprehensive market size estimations and growth projections
• Expert analysis of driving forces shaping market dynamics
• Granular market segmentation by medication class and distribution channel
• Detailed profiles of industry leaders and their competitive strategies
• Illuminating insights into emerging trends and growth catalysts
• Future-oriented market outlook and strategic recommendations

DROCT

The report offers deep insights into the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market, enabling stakeholders to make informed decisions and capitalize on growth opportunities.

Pricing Analysis

The report provides insights into the pricing trends of SHPT treatments and the factors influencing price variations.

Import And Export Analysis

The report analyzes the import and export trends of SHPT treatments in the context of the U.S. market.

Segmentation

The report segments the U.S. Secondary Hyperparathyroidism (SHPT) Treatment Market by drug class, distribution channel, and other relevant parameters.

Patent/Trademark Analysis

The report analyzes the patent and trademark landscape related to SHPT treatments in the U.S. market.